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We report on adsorption and release of the anticancer drugs cisplatin and transplatin from mesoporous silica nano-
materials, emphasizing the differences between cisplatin and its much less toxic isomer. Two types of particles,MCM-41 and
SBA-15, were used, either as just synthesized or after calcination to remove the templates. The particles were characterized by
TEM,nitrogen physisorption, and elemental analysis. TheUV-vis spectra of cisplatin and transplatinwere obtained and the
intensities of several bands (205-210 nm, 210-220 nm, 220-235 nm, and 300-330 nm) were found proportional to drug
concentrations, allowing their use for measuring drug concentration. To evaluate drug adsorption by nanoparticles,
nanoparticles were incubated in drug solutions and removed by centrifugation, after which the supernatants were scanned by
spectrometer to determine drug remaining. Itwas found that calcinedMCMadsorbed less cisplatin or transplatin per particle
than as-synthesized MCM. SBA nanoparticles adsorbed slightly more cisplatin than MCM, and slightly less transplatin.
Measurements of drug adsorption as a function of time show that drug is rapidly adsorbed by all particles studied. This rapid
adsorption is probably associated with adsorption of drug on the external surfaces of the particles as well as the possible
physisorption within the surfactant assemblies or by replacing the surfactant molecules or ions in the case of the as-
synthesized materials. For calcined SBA particles, it is followed by a slow take-up of drug, perhaps due to the internal pores.
There is no slow take-up by as-synthesized SBAparticles or by either as-synthesized or calcinedMCMparticles.Measurement
of the release of platinumdrugs from nanoparticles previously soaked in drug solutions showed a substantial quick release for
all particles and both drugs. This was followed by a slow release of Pt species in the case of transplatin in calcined SBA.
Introduction
The tunable syntheses of functionalized nanomaterials have
promised a great future for their applications in biological systems,
suchasdrugorbimolecular delivery andmedical imaging.1-4 It has
beenwell recognized that biocompatibility of nanoparticles depends
on their physical and chemical properties. Changes in material
composition, particle size, shape, surface area, or, if applicable,
porosity and functional groups could induce different biological
effects. The potential nanotoxicity becomes very important when
nanoparticles serve as drug hosts.5-9 Moreover, the physical
properties of nanomaterials determine their capacities to load
and unload guest molecules. Therefore, finding nanoparticles to
serve as effective drug delivery vehicles demands efforts in reducing
cytotoxicity, improving site-specific delivery, and managing drug
adsorption or release properties in a controlled manner.
Since the debut of MCM-41 on the nano stage in the early
1990s,10 mesoporous silica nanomaterials (MSN) have shown
exceptional promise for biological applications, gene and drug
delivery in particular, due to their large surface area and well-
ordered porosity.2-4 Because of recent achievements in size and
morphology control,11 mesoporous silica nanoparticles (MSN)
offer the possibility of lodging a variety of drugmolecules.12-23 In
addition, functionalized groups tethered, either inside the meso-
porous channels or on the external surfaces, may facilitate drug
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adsorption and release through customized chemical affinity.
Two of the most commonMSN, SBA-15, and MCM-41, display
well-defined arrays of pores and cylindrical mesostructures
packed in hexagonal geometry.24 The differences between
MCM-41 and SBA-15-type MSN are mainly in pore dimension
and to some extent in particle size and wall thickness. These
nanomaterials are currently considered as promising carriers for
drugs and biomolecules. We recently reported that MSN inter-
fered with intracellular mitochondrial functions, including oxy-
gen consumption and ATP formation, in a manner dependent on
their physical properties.9
The nature of the transported drug may also complicate its
delivery by nanomaterials. The chemical reactions of drugs
(including isomerization) determine their therapeutic effect, but
may also affect drug loading by nanoparticles. For instance, Δ9-
tetrahydrocannabinol (THC), a double-bond isomer ofΔ8-THC,
exhibits a much higher psychotropic potency to affect central
neural system than Δ8-THC does.25 Cisplatin, the first platinum-
based chemotherapy drug, is much more cytotoxic than its
geometric isomer transplatin. The isomers yield different anti-
tumor activity and toxicity profiles, including reactivity with
DNA and induction of apoptosis.26,27 They should also differ in
their adsorption and release bynanoparticles, since hydrophilicity
or solubility may be different for different isomers.25
Here we report on the significant differences in adsorption and
release properties of cisplatin and its less toxic isomer transplatin,
within and from mesoporous silica nanomaterials. We first
investigate, using UV-vis spectroscopy, the encapsulation of
cisplatin and transplatin into two types of MSN, SBA-15 and
MCM-41. We compare the two materials as-synthesized with the
materials after calcination to show drug adsorption inside the
mesoporous channels. We stress the effect of the difference
between the isomeric platinum drugs on their adsorption by
MSN. The time-dependent release behaviors of platinum drug-
loaded nanomaterials are studied subsequently.
Experimental Section
Materials and Reagents. Phosphate-buffered saline (1x PBS,
without Mg2þ and Ca2þ, pH=7.4) was purchased from Medi-
atech (Herndon,VA).Cetyltrimethylammoniumbromide (CTAB),
tetraethylorthosilicate (TEOS) and poly(ethylene oxide)-block-
poly(butylene oxide)-block-poly(ethylene oxide) (Pluronic P123
or P123, MW=5800) were obtained from Sigma-Aldrich. Cis-
platin and transplatin (yellow powder, m.w. 300.05) were obtai-
ned from Sigma-Aldrich and dissolved in PBS before experi-
ments. Cisplatin (1 mg/mL for injection, ∼3.3 mM in 154 mM
NaCl) was purchased from American Pharmaceutical Partners
(Schaumburg, IL).
Synthesis andCharacterization of SBA-15 andMCM-41.
Mesostructured MCM-41 and SBA-15 type nanomaterials (or
labeled here as MCM and SBA) were synthesized by previously
reported procedures with minor modification,1-5 both followed
by calcinations to remove the surfactants. The particles were
used as-synthesized (SBAsyn and MCMsyn) or further calcined
(SBAcal and MCMcal). Nitrogen physisorption measurement
was then carried out for all the nanomaterials at 77 K after
outgassing the samples at 433 K for 2 h, using a Micromertitics
Tristar 3000 volumetric adsorption analyzer. The characterizations
also yielded total BET surface area and pore size distributions for
each sample. Besides, elemental analysis was employed as well to
measure the C, H, and N contents in all the particles by weight.
Correction of UV-Vis Spectra. Absorption spectra of
solutions of cisplatin or transplatin were measured between 190
and 800 nm. Inorder to eliminate the effect of instrumental errors,
each spectrum obtained was corrected as follows: The measured
absorbance intensities for wavelengths between 800 and 500 nm
were fitted to a line. Since the drugs do not absorb in this region,
these small intensities represent an instrumental artifact. The
linear function, extended to the spectral region from 500 to 200 nm,
was subtracted from the original absorbance readings. The
resulting subtracted intensities were utilized in all calculations
throughout this study.
Adsorption of Platinum Compounds by Nanomaterials.
Cisplatin and transplatin were dissolved in PBS immediately
before the experiments. One of four different nanoparticles,
MCMsyn, MCMcal, SBAsyn, and SBAcal, was added into the
drug solution and soaked with constant stirring. After the desired
time period, 2 mL solution was removed from the container and
centrifuged at 5585g for 10 min to remove the nanoparticles. The
resulting supernatant was carefully collected and the residual
concentration of platinum compounds was then determined spec-
troscopically, using a Lambda 950 UV-vis spectrophotometer
(PerkinElmer). However, it was found that centrifugation did not
suffice to completely remove silica from solution. The residual
nanoparticle fragments (and possibly, template) scattered light
at the wavelengths used for measuring drug concentration, which
appeared as absorption. To correct this, we measured the
apparent absorption spectrum of the supernatant from solutions
containing no drug, inwhich nanoparticles had been soaked. This
spectrum was subtracted from the absorption spectrum of the
supernatant obtained by centrifuging a drug solution containing
nanoparticles at the same concentration.
HPLC Analysis.We used HPLC to show any possible drug-
surfactant chemical interaction was absent. The possible inter-
action between platinum drugs and P123 or CTAB in the solu-
tions was studied by a Beckman reversed-phase HPLC system,
which consisted of an automated injector (model 507e) and a
pump (model 125). The column, 4.6 250 mm Beckman Ultra-
sphere IP column, was operated at room temperature (25 C) at a
flow rate of 0.5 mL/min. The run time was 30min and the mobile
phase was 1% (v/v) methanol in dH2O. Here, 1 mM samples of
cisplatin and transplatin in PBS were incubated with or without
10 mg/mL CTAB or P123 for 16 h. Then a 40 μL solution from
each condition was diluted in 2mL of dH2O, and 10 μL injections
were run on HPLC. The detection wavelengths were fixed at
210 and 300 nm, respectively. A single peak was observed at
retention time∼5 min in all the samples and the area of this peak
was evaluated. The variation of peak area in all conditions was
<5.1%. In each condition measurements were performed again
48 h later. The interday variations of peak areas for the same
injection were found to be between 0.1% and 5.9%. Thus, it is
clear that the solution of platinum drugs is stable and there is no
chemical reaction between platinum drugs and templating chemi-
cals (CTAB or P123).
Results and Discussion
The syntheses of theMCM-41 and SBA-15 types ofMSN were
carried out by supramolecular self-assembly techniques, follow-
ing the reported procedures with minor modification10,28-31 (see
Supporting Information for details). The nanomaterials as
synthesized were labeled SBAsyn and MCMsyn, respectively.
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In both cases, synthesis was followed by calcination to remove the
template, resulting in the formation ofMSN,denoted asMCMcal
and SBAcal, respectively. The transmission electron microscopy
(TEM) images (Figure 1) show that the calcined MCM-41
materials are rather regular spherical or oval shaped particles
(∼350 nm in diameter), while the calcined SBA-15 materials are
irregularly shaped particles spanning a larger size range (300-650
nm). The TEM images also indicate that thematerials have highly
hexagonally ordered mesoporous structures. The materials were
further characterized by surface area measurements using nitro-
gen physisorption. The mesoporous nanoparticles show Type IV
isotherms with steep capillary condensation steps (see Supporting
Information, Figure S1), confirming the presence of uniform
mesopores with large surface areas.
The adsorption of cisplatin or transplatin by SBA and MCM-
type nanomaterials was derived from the decrease in concentra-
tion of platinum drug in the solution after exposure to the
nanomaterials. For calibration purposes, the platinumdrugswere
Figure 1. TEM images of calcined MCM-41 (A) and SBA-15 (B) that are labeled as MCMcal and SBAcal, respectively.
DOI: 10.1021/la904695a 8917Langmuir 2010, 26(11), 8914–8924
Tao et al. Article
dissolved in PBS (pH = 7.4) and the solutions were measured
spectroscopically. The wavelength was scanned from 800 to 190
nm. UV-vis spectra of 1.0 mM cisplatin and transplatin in PBS
are shown in Figures 2A and 2C, respectively. Each spectrumwas
corrected by background subtraction as stated in the Experi-
mental Section. Figure 2A shows that cisplatin displays a strong
absorption (charge-transfer band) at 208 nm, with molar extinc-
tion coefficient (εM) of 3145 M
-1 cm-1. In addition, it exhibits a
much weaker band at 300 nm, with εM calculated as 117 M
-1
cm-1 (from the d-d transitions of the square planar Pt2þ ion.32)
Absorption was measured for cisplatin concentrations from
20 μM to 1.2 mM. To minimize possible errors of instrumental
origin such as slight shifts in wavelength over time, we report,
instead of absorbance at a single wavelength, the absorbance over
a band, i.e. the sum of intensities for a range of wavelengths.
In Figure 2B are shown integrated intensities for cisplatin for
205-210 nm (open squares), 210-220 nm (filled squares),
220-235 nm (open triangles) and 300-330 nm (filled triangles),
as functions of drug concentration. We avoided wavelengths
below 200 nm, since the spectrophotometer has its measurement
limit at 190 nm and the intensities obtained in the neighboring
region are not reliable. Linear regression of band intensity vs
concentration for cisplatin gave the following results ([cisplatin] is
in μM): For the 205-210 nm band, S (integrated intensity) =
(254.0( 13.0)10-4 [cisplatin]( (0.725( 1.602) (r2=0.906); for
the 210-220 nm band, S= (185.9 ( 13.2) 10-4 [cisplatin] þ
(0.958 ( 0.965) (r2=0.952); and, for the 220-235 nm band S=
(105.5 ( 4.5) 10-4 [cisplatin] þ (-0.053 ( 0.325) (r2=0.982).
The intercept is statistically zero in each case. For the 300-330 nm
band, S=(20.5( 0.7)10-4 [cisplatin]þ (-0.266( 0.054) (r2=
0.987), the slightly negative intercept probably being due to the
low reliability of the small intensities obtained for low concentra-
tions. An intercept which is statistically zero means that band
intensity is proportional to drug concentration, indicating that the
absorbance all originates with the same compound and that any
band intensity can be used as a measure of drug concentration.
In Figure 2C, the spectrumof transplatin at 1.0mM shows two
differences from that of the cis-isomer. First, there is an absorp-
tion peak at 203 nm (εM=2013M
-1 cm-1), which is weaker than
the one for cisplatin at 208 nm. This implies a weaker charge-
transfer transition for the trans-compound. Second, instead of
one band near 300 nm in the case of cisplatin, there appear two
bands with peaks at 269 and 313 nm (εM=34 and 23M
-1 cm-1,
respectively), probablydue to thedistorted d-d transitionswithin
a trans square planar structure. Band intensities for [transplatin]
from60 μMto 1.6mMare shown in Figure 2D. Aswith cisplatin,
the sums of the intensities for 205-210 nm (open squares),
210-220 nm (filled squares), 220-235 nm (open triangles), and
300-330 nm (filled triangles) were measured, and linear regres-
sionwas carried out on band intensity vs drug concentration. The
following results were obtained ([transplatin] is in μΜ): for
the 205-210 nm band S (integrated intensity) = (87.6 ( 1.1)
10-4 [transplatin] þ (0.110 ( 0.091) (r2 = 0.999); for the 210-
220 nm band, S= (94.3 ( 0.8) 10-4 [transplatin] þ (0.049 (
0.068) (r2=0.999); for the 220-235 nm band, S=(48.9( 0.4)
10-4 [transplatin] þ (0.042 ( 0.032) (r2 = 0.999); for the 300-
330 nm band, S=(5.7 ( 0.2) 10-4 [transplatin] þ (-0.006 (
0.018) (r2=0.988). The intercept is statistically zero in each case;
therefore, intensities of all bands are proportional to [transplatin],
proving that all bands are due to platinum-containing species.
Thus, all band intensities can be used to measure transplatin con-
centrations.
Figure 2. UV-vis spectrumof 1.0mMcisplatin (A) or transplatin
(C) freshly dissolved in PBS. Integrated intensities from cisplatin
(B) and transplatin (D) for 205-210 nm (open squares), 210-
220 nm (filled squares), 220-235 nm (open triangles) and 300-
330 nm (filled triangles), as functions of [platinum drugs] in μM.
Linear regressions of these integrated intensities versus drug con-
centration were employed, giving fitted lines for 205-210 nm
(dashed line), 210-220 nm (solid line), 220-235 nm (dotted line),
and 300-330 nm (solid line).
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Since nanoparticle suspensions appear to absorb radiation, we
investigated the apparent absorption spectra of nanoparticle
suspensions. Nanoparticles (MCMsyn and MCMcal, SBAsyn,
and SBAcal) were added to PBS (10 mg/mL for each sample),
sonicated until well suspended and then centrifuged. The spectra
of the supernatants are shown in Figure 3A. The “absorptions”
are due to the scattering from the nanoparticle residues (possibly
including the residual surfactants) in solution. For solutions with
SBAsyn residues (solid gray line), the spectrum shows peak
“absorption” at 203 nm, near the region of strong absorption
for cisplatin and transplatin. The scattering intensities near 300 nm
are much smaller, but still high compared to those of platinum
drugs. For solutions with SBAcal residues (dotted gray line), the
major absorption around 200 nm vanishes, but the scattering
intensities in the other regions are generally increased. Scattering
is lower forMCMnanoparticles than for their SBA counterparts,
possibly because, for the same mass, there are fewer MCM-type
particles than SBA-type particles. A maximum “absorbance”
occurred at 202 nm for the solutions with MCMsyn residues
(solid line), but there is no evident peak in the spectrum of
solutions with MCMcal residues (dotted line).
We added different amounts of nanoparticles (1, 2, 5, 10, 15,
and 20mg/mL) to PBS solutions, centrifuged out the precipitates,
and measured the scattering intensities of the nanoparticle resi-
dues. As for the spectra of platinum solutions, the intensities from
210 to 220 nm or from 300 to 330 nmwere combined. Results are
shown in Figures 3B (MCM) and 3C (SBA). In some cases, the
intensities are appreciable compared to the absorbance of cispla-
tin or transplatin in the same wavelength regions. In Table 1, we
show the results of the linear fits for four spectral bands for all
four particles. For each of the 16 cases are listed the slopes and
y-interceptswith their statistical errors, plus theR2 value. It can be
Figure 3. (A)Pseudoabsorption spectraofnanoparticles.The10mg/mLSBAsyn (solidgray line), SBAcal (dottedgray line),MCMsyn (solid
line), andMCMcal (dotted line) samples were first dissolved in PBS, respectively. The suspensions were sonicated and centrifuged at 5,585 g
for 10min.The supernatantwas then collected for spectroscopicmeasurements.The resulting “absorptions” are due to the scattering fromthe
nanoparticle residues in the solutions. The scattering intensities of MCM (B) and SBA (C) nanoparticle residues were thus plotted versus
original addition of nanoparticles (1, 2, 5, 10, 15, and 20mg/mL, respectively). Band intensities for 210-220 nm (upper panel) or 300-330 nm
(lower panel) are fitted into linear functions of the amount of nanoparticles that were originally added in PBS. “þ” symbols and solid line for
particles as-synthesized; “4” symbols and dashed line for particles calcined.
DOI: 10.1021/la904695a 8919Langmuir 2010, 26(11), 8914–8924
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seen that the y-intercept differs significantly from zeroonly for the
300-330 nm band of MCMcal (this apparent exception may be
due to the experimental errors in the small intensities). An
intercept close to zero, with largeR2, shows intensity of scattering
by residual particles is proportional to the concentration of
nanoparticles before centrifugation, which implies that multiple
scattering is unimportant. The proportionality justifies using the
fits of Table 1 to estimate the scattering due to nanoparticle
fragments and templating material. This scattering intensity can
then be subtracted frommeasured absorption band intensities for
drug þ nanoparticle conditions. In every case (including the
300-330 nm band of MCMcal, which has very small intensity),
the error in the estimated scattering intensity is small enough so
that the subtraction does not introduce large errors.
It is possible that the apparent absorption in the spectra of as-
synthesized SBA and MCM nanomaterials results from strong
absorption by surfactant residues. Experiments were thus per-
formed to verify the influence of these templating chemicals on
optical absorbance. We dissolved 5.0 mg/mL Pluronic P123 or
CTAB (the surfactants for SBA or MCM synthesis) in PBS at
40 or 80 C respectively, reproducing the temperature at which
SBA or MCM had been synthesized. Solutions were well mixed
and collected for centrifugation at 23,000 X g, and no precipitate
was observed. Figure S2 in the Supporting Information shows the
spectra of P123 (dotted line) and CTAB (solid line) in PBS,
demonstrating that both P123 and CTAB absorb near 200 nm.
The P123 spectrum has a peak at 201 nm, and the CTAB solution
has one at 209 nm, although neither solution exhibits noticeable
absorption in the region 250-350 nm. Therefore, the template
does contribute to the apparent absorption near 200 nm in the
spectra of MCMsyn and SBAsyn in PBS.
The potential chemical reaction between platinum drugs and
P123 orCTAB templating agents was next investigated byHPLC.
Cisplatin and transplatin (1 mM in PBS) were incubated with or
without 10 mg/mL CTAB or P123 for 16 h (these concentrations
are much higher than those used in our syntheses). The resultant
solutions were diluted 50 times in PBS and run on HPLC, with
detection at 210 and 300 nm, respectively. Under all conditions,
the HPLC peaks possessed the same retention time and area
under the curve (results not shown), suggesting no chemical
reaction or interference between platinum drugs and templating
chemicals.
In order to measure the adsorption of cisplatin or transplatin
by SBA and MCM-type nanomaterials, solutions of cisplatin or
transplatin (1 mM in PBS) were prepared 16 h before adding 1, 2,
5, 10, 15, or 20 mg/mL nanoparticles (hydrolysis of platinum
drugs is complete in 16 h).33 Nanoparticles were removed by
centrifugation after 30min incubation, and the supernatants were
scanned by spectrophotometer. Intensities for each of three bands
(205-210, 220-235, and 300-330 nm) were obtained for each
amount of nanoparticles. The corresponding intensities for the
nanoparticle residues were subtracted, to give the absorption of
the platinum drug remaining in solution.
Band intensities after subtraction of nanoparticle residue
pseudoabsorption were plotted against original nanoparticle
additions. The results for MCM materials are shown in Figure
4A. The four panels are for as-synthesized MCM particles with
cisplatin (upper left), calcined MCM particles with cisplatin
(upper right), as-synthesized MCM particles with transplatin
(lower left), and calcined MCM particles with transplatin
(lower right). Expecting drug uptake to be proportional to the
amount of nanoparticles, linear fits are shown for each band.
In Table S3 (Supporting Information) we give, for each of the
12 cases, the slopes and the y-intercepts from the linear fits. These
are used to calculate the fraction of drug that would be removed
by 5 mg/mL of nanoparticles using
fraction 5 ¼ -½slope 5=½intercept ð1Þ
The calculation is given in Table S3 (Supporting Information)
with the statistical error, which comes mostly from the statistical
uncertainty in the slope. It should be the same, within statistical
error, for all three bands. This is clearly the case for MCMsyn
particles with cisplatin, and less definitively for the other three
cases, where statistical errors are larger. The results (average þ
sample standard deviation) are given in Table 2, columns 2 and 3.
Since MCMsyn contains 47.6% CTAB by mass, the results
should be divided by 0.524, giving columns 4 and 5. Fraction 5
forMCMsynþ cisplatin is greater than forMCMcalþ cisplatin.
For adsorption of transplatin, the difference between syn and cal
is even slightly greater. It is also clear that both synthesized and
calcined MCM particles adsorb slightly more transplatin than
cisplatin.
The same experiments and calculations were performed to
obtain adsorption profiles of cisplatin and transplatin by SBA
nanomaterials. Band intensities for three bands (205-210, 220-
235, and 300-330 nm) were obtained, and intensities for the
nanoparticle residues were subtracted to give the net absorption
due to platinum drug. These were plotted against original addi-
tion of nanoparticles, with linear fits, as shown in Figure 4B. The
slopes and the y-intercepts, with statistical errors, are listed in
Table S4 (Supporting Information). Calculated values of fraction
5, which were consistent between bands within the stated errors,
are shown in Table 2. After correcting the results for SBAsyn by
dividing by 0.671 (the as-synthesized particles contain 32.9%
P123 by mass), we find that SBAsyn particles adsorb more of the
platinum drugs than the calcined particles. Furthermore, both
synthesized and calcined SBA particles adsorb more transplatin
than cisplatin. The adsorption of cisplatin and transplatin by
SBAcal nanoparticles is somewhat less than their adsorptions by
MCMcal nanomaterials. This is consistent with the higher surface
area of MCMcal compared to SBAcal for the same mass (Table
S1) (Supporting Information). It is also interesting that the two
isomers show different adsorptions by the same nanomaterial.
The next study involved varying the amount of platinum com-
pounds, to see the effect on their adsorptions by a fixed amount of
nanoparticles. Solutions with various concentrations of cisplatin
Table 1. Linear Fits to Band Intensities from Scattering
of SBA and MCM
nanoparticle band (nm) slope intercept R2
SBAsyn 205-210 0.337( 0.031 0.352( 0.262 0.975
210-220 0.475( 0.026 0.285( 0.218 0.991
220-235 0.250( 0.027 0.317( 0.309 0.954
300-330 0.034( 0.005 0.044( 0.057 0.919
SBAcal 205-210 0.012( 0.006 0.043( 0.049 0.599
210-220 0.040( 0.010 -0.003( 0.082 0.849
220-235 0.029( 0.017 0.013( 0.186 0.438
300-330 0.015( 0.005 0.013( 0.060 0.650
MCMsyn 205-210 0.189( 0.006 0.095( 0.066 0.996
210-220 0.233( 0.013 0.120( 0.147 0.988
220-235 0.139( 0.016 -0.040( 0.176 0.952
300-330 0.038( 0.008 -0.102( 0.089 0.850
MCMcal 205-210 0.007( 0.001 0.008( 0.015 0.859
210-220 0.020( 0.002 0.051( 0.022 0.962
220-235 0.026( 0.003 0.059( 0.032 0.953
300-330 0.034( 0.003 0.148( 0.029 0.977
(33) Berners-Price, S. J.; Appleton, T. G. Chemistry of Cisplatin in Aqueous
Solution: Pt Drugs in Cancer Therapy; Humana Press: Totowa, NJ, 2000.
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and transplatin were prepared 16 h before mixing with 5 mg/mL
different nanoparticles. After addition, nanoparticles were quickly
removed by centrifugation and the supernatants were measured
spectroscopically (preparation time∼1/2 h). If the amount of drug
that nanoparticles can adsorb were limited, the concentration of
adsorbed drug would be given by the Langmuir isotherm (eq 2):
cads ¼ kðc - cadsÞ
1 þ Kðc-cadsÞ ð2Þ
where c is the initial drug concentration in solution. According to
this, cads is proportional to (c-cads), the platinum drug concen-
tration remaining in solution, for small c and approaches k/K for
large c, so that k/K is the maximum concentration that can be
adsorbed. We measure (c-cads) spectroscopically, where, from
the Langmuir isotherm,
ðc-cadsÞ ¼
Kc - 1 - k þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðKc - 1 - kÞ2 þ 4Kc
q
2K
ð3Þ
so that a plot of drug concentration remaining in solution vs
initial drug concentration is concave upward.
Plots of measured band intensities (proportional to drug
concentration) vs initial drug concentration were fitted to linear
and quadratic forms. Results for all four conditions for MCM
particles, three bands for each, are shown in Table 3, including
R2 for both fits. Fitting to quadratics did not improveR2, or led to
concave downward functions. This means that curvature is not
important, so there is no evidence of saturation. The correspond-
ing results for SBA particles are in Table 4. Fitting these absorp-
tion intensities to quadratics did not improveR2, or led to concave
downward functions, showing that there is no evidence of satura-
tion for SBA either.
To investigate time-dependent drug adsorption of the platinum
drugs by the nanoparticles, nanoparticles were added to 1 mM
cisplatin or transplatinPBS solutions, 5mg/mLSBA (Figure 5) or
MCM (Figure 6) at time zero, with stirring continued throughout
the experiments. These drug solutions were freshly made, so that
hydrolysis of the platinum drugs was not complete at time zero.
At each time point, 2.0 mL of the mixture was taken for centrifu-
gation and the supernatant was scanned in the spectrophoto-
meter. After background subtraction (see Experimental Section),
band intensities were calculated. Drug-free PBS solutions with
addition of 5 mg/mL nanoparticles were treated similarly: band
intensities, due to scattering from nanoparticle residues, were
calculated after background subtraction. These were in turn sub-
tracted from the band intensities from drug-nanoparticle solu-
tions to give absorbance of the remaining drug in solution.
The band intensities for drug alone (triangles) and for drug þ
nanoparticles (filled and half-filled squares) are plotted against
time in Figures 5 and 6 (time= time of sampling þ0.5 h, repre-
senting the preparation timebefore samples could bemeasured on
the spectrometer). For drug alone, we show the best fit to the
function A - Be-kt, which represents the effect of hydrolysis.
For cisplatin, the hydrolysis rate constant k is known to be
0.186 h-1,33 so only two parameters are varied in the fit. For
transplatin, k is not known, so three parameters are varied. We
find k=0.586 h-1 from the 205-210 nm band and k=0.551 h-1
from the 300-330 nm band, showing that transplatin hydrolyzes
three times as fast as cisplatin.
Figure 5 shows the change in the platinum-drug concentration,
due to the loading by SBA nanoparticles, with time. It is obvious
that, at the first time point (1/2 h), the intensities are always much
lower for solutions exposed to nanoparticles than for solutions of
drug alone, showing rapid adsorption of drug by the nanoparticles.
The latter intensities show a sharp increase over the first few
Figure 4. Band intensities of absorption spectra of platinumdrugs
remaining in solutions after centrifuging out MCM (A) and SBA
(B) nanoparticles. Various amounts of the nanoparticles (1, 2, 5,
10, 15, or 20 mg/mL) were added into 1 mM cisplatin (Cis) or
transplatin (Trans) PBS solutions that had been aged for 16 h.
After 30 min incubation, nanoparticles were removed by centrifu-
gation. Band intensities for 205-210 nm (9), 220-235 nm (2), and
300-330 nm (b) are plotted as functions of original additions of
nanoparticles.
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hours, due to the hydrolysis of the drugs, which is not shown by
the intensities for drug þ nanoparticles. This shows further
adsorption of platinum drug by SBA nanoparticles. In Figure 5,
we show least-squares linear fits to measured band intensities vs
time for SBAsyn (filled squares and solid lines) and SBAcal (half-
filled squares and dotted lines) nanoparticles. The slopes with the
statistical errors are listed in Table S5. In each of the four cases,
the slope is significantly larger for SBAsyn particles than for
SBAcal particles. Since the intensity is increased byhydrolysis and
decreased by removal of drug by the nanoparticles, this implies
that, after the first half hour, calcined SBA particles take upmore
drug than do synthesized SBA particles. However, the y-inter-
cepts are the same for synthesized and calcinedparticles in three of
four cases (the other, 205-210 nm for SBAsyn þ cisplatin, has
too much scatter to be useful). After the mass correction between
syn and cal particles, the adsorptionof drug in the first half hour is
seen to be greater for the syn particles. Subsequently, the calcined
particles slowly encapsulate additional drug into their inner pores
(which are blocked in the synthesized particles).
The corresponding experiments on MCM nanoparticles differ
in one respect from those onSBAparticles. The cisplatin solutions
used for the MCM-particle experiments were made by diluting
commercial cisplatin solutions, so that hydrolysis has already
occurred, and there is no rapid rise in band intensity. Therefore,
the band intensities for cisplatin alone are fitted to lines, as shown
in Figure 6, parts A and C. The transplatin solutions, like all the
solutions used with SBA, were made freshly from the powdered
drug, so the transplatin band intensities are fitted to the function
A- Be-kt as above. All the other data sets, band intensity vs time
for either drug in the presence of either type of nanoparticle, are
fitted to lines. The y-intercepts of these fits are almost the same.By
comparing the intensity at t=0.5 h for drug alone with that for
drug exposed to nanoparticles, one can estimate the fraction of
drug that was rapidly removed by the nanoparticles. For cisplatin
withMCMsyn particles, we get 0.28( 0.02 from the 205-210 nm
band and 0.25 ( 0.07 from the 300-330 nm band. For cisplatin
with MCMcal particles, we get 0.18( 0.05 and 0.19( 0.04 from
the two bands. For transplatin, there is toomuch scattering in the
Table 2. Fraction 5 (Fraction of Drug That Would Be Absorbed by 5
mg/mL of Nanoparticles) with Standard Deviation, before and after
Correction for Weight Fraction of Silicaa
before correction after correction
system
average
fraction
standard
deviation
average
fraction
standard
deviation
MCMsyn þ
cisplatin
0.077 0.006 0.147 0.011
MCMcal þ
cisplatin
0.104 0.061 0.104 0.061
MCMsyn þ
transplatin
0.167 0.082 0.319 0.156
MCMcal þ
transplatin
0.120 0.066 0.120 0.066
SBAsyn þ
cisplatin
0.091 0.019 0.136 0.028
SBAcal þ
cisplatin
0.089 0.061 0.089 0.061
SBAsyn þ
transplatin
0.162 0.073 0.241 0.109
SBAcal þ
transplatin
0.110 0.057 0.110 0.057
aThe table indicates that transplatin is absorbed about twice as much
as cisplatin forMCMsyn and SBAsyn, which indicates a very significant
difference. For theMCMcal and SBAcal, there is an increase adsorption
of transplatin in both materials, while MCMcal adsorbs more platinum
compounds than SBAcal.
Table 3. Drug Adsorbed by 5 mg/mLMCMNanoparticles, Measured Spectroscopically, Where Saturation Would Give a Quadratic Function of
Drug Concentration
drug particle band (nm) slope y-intercept R2, linear R2, quadratic
cisplatin synthesized 205-210 3.266 12.595 0.624 0.861 (D)a
220-235 13.539 1.545 0.999 0.999
300-330 2.224 -0.052 0.998 0.999
calcined 205-210 4.580 11.790 0.665 0.739 (D)a
220-235 14.083 0.410 0.999 0.999
300-330 2.354 0.013 0.998 0.998
transplatin synthesized 205-210 5.845 0.592 0.989 0.995 (D)
220-235 3.274 0.356 0.974 0.956
300-330 0.154 0.218 0.298 0.173
calcined 205-210 6.351 0.133 0.950 0.950
220-235 3.752 0.120 0.956 0.956
300-330 0.432 0.118 0.946 0.947
a (D) in R2 from quadratic means concave downward and so unacceptable for Langmuir.
Table 4. Drug Adsorbed by 5 mg/mL SBA Nanoparticles (Measured Spectroscopically); Saturation Would Give a Quadratic Function
of Drug Concentration
drug particle band (nm) slope y-intercept R2, linear R2, quadratic
cisplatin synthesized 205-210 1.940 12.876 0.660 0.717 (D)a
220-235 6.577 5.040 0.957 0.986 (D)a
300-330 2.375 -0.139 0.952 0.980
calcined 205-210 9.114 6.872 0.860 0.877
220-235 9.519 0.951 0.984 0.990 (D)a
300-330 1.971 -0.284 0.893 0.919
transplatin synthesized 205-210 4.699 2.011 0.986 0.990 (D)a
220-235 3.106 -0.189 0.977 0.986 (D)a
300-330 0.468 -0.349 0.506 0.520
calcined 205-210 5.368 -0.449 0.884 0.939
220-235 2.858 -1.176 0.839 0.891
300-330 -0.121 0.173 0.059 0.089
a (D) in R2 from quadratic means concave downward and so unacceptable for Langmuir.
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300-330 nm band intensities to get any meaningful information;
from the other band, we find the fraction removed to be 0.25 (
0.02 for MCMsyn particles and 0.33 ( 0.01 for MCMcal
particles. Thus, the fraction of cisplatin adsorbed in 0.5 h is
greater for MCMsyn particles than for MCMcal particles; for
transplatin, the situation may be reversed. However, after correc-
tion for the different masses of syn and cal particles, we findmore
adsorption of both drugs per particle for syn.
To study the adsorption of drugs at longer time, we consider
the slopes of the lines in Figure 6. Table S6 in the Supporting
Information gives the slopes of these lines, with the statistical
errors. For the MCM particles, it does not seem that calcination
(forming the mesoporous channels) leads to a slower adsorption
of drug. (The only case in which the slope is appreciably more
negative forMCMcal than forMCMsyn is the last, but the scatter
makes the results doubtful.) Generally, the slopes are all very
small, indicating very little slowadsorptionof platinumdrugs into
MCM nanoparticles.
Finally, the release of the cisplatin and transplatin drugs from
drug-loaded SBA and MCM nanoparticles was studied. Nano-
particles (5mg/mL)were first soaked in 1mMPBSdrug solutions
for 48 h. Afterward, they were removed from the solution by
centrifugation, and resuspended in fresh PBS at concentrations of
5 mg/mL. At various times (i.e., 2, 4, 6, 8, 12, 24, and 48 h),
samples were taken from the suspension and centrifuged to
remove the particles. The supernatant from each sample was
measured by spectrophotometer. Intensities of three bands
(205-210, 220-235, and 300-330 nm) were measured with the
results given in Table S7 (Supporting Information).
In each case, we have fit the band intensity as a function of time
to a line; Table S7 (Supporting Information) gives the y-intercept
and the slope with the statistical errors. The y-intercept (band
intensity extrapolated back to t=0) gives the concentration of
platinumdrugs in the solution after a rapid release of drug, if any,
has occurred. The slope, if greater than zero, shows the slow
release of drug, presumably from the internal mesopores of the
nanoparticles. In fact, the slope is equal to zero within the
statistical error (which is sometimes quite large) in all but a few
cases. These exceptions, underlined in Table S7, correspond to
transplatinþ calcined SBA. Note that only the calcined particles
can adsorb drug into interior pores, from which slow release is
likely to occur.
Figure 5. Integrated intensities of adsorption spectra resulting from platinum drugs remaining in solutions after centrifuging out SBA
nanoparticles. Platinum drugs were freshly dissolved in PBS solution, without (2) and with 5 mg/mL SBAsyn (9) or SBAcal (≤). The sum
of intensities for 205-210 nm (upper panel) and 300-330 nm (lower panel) were least-squares fitted to functions of time. For drug alone
(upper solid line), the best fit to the functionA- Be-kt represents the effect of hydrolysis; for drug loaded by either SBAsyn (lower solid line)
or SBAcal (dashed line), linear regressions were adopted. Time zero corresponds to the addition of nanoparticles into freshly made drug
solution.
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Tomeasure the extent of rapid release of drug, we subtract the
scattering of the nanoparticle residues (measured as indicated
above and given in Table S7 (Supporting Information)) from the
y-intercept in Table S7 (Supporting Information). For SBAsyn
particles with cisplatin or transplatin, the y-intercept for the first
band is less than the residual intensity, but not by more than the
statistical error, while the y-intercepts for the other two bands are
greater than the residual intensities. This suggests that substantial
amounts of cisplatin and transplatin are released quickly from the
SBAsyn nanoparticles. For SBAcal particles, the three band
intensities from residual scattering are much smaller than the
corresponding y-intercepts for cisplatin and transplatin. There is
no doubt that considerable amounts of both drugs are released
quickly from the SBAcal nanoparticles. For cisplatin þ MCMsyn,
the y-intercepts in Table S7 (Supporting Information) are
significantly greater than the residual intensities for the
second and third bands, and about the same for the first, indicat-
ing that cisplatin is readily released by these particles. For
transplatin þ MCMsyn, the y-intercepts are smaller than the
residual intensities, suggesting that theMCMsyn particles do not
release the surface-bound transplatin. Finally, the band inten-
sities from residual scattering fromMCMcal particles are smaller
than the y-intercepts; we hence conclude that the MCMcal
particles readily release most of the bound cisplatin and trans-
platin.
Conclusions
We studied the adsorption and release of both cis- and trans-
platin by two types of particles (SBA and MCM), either as-
synthesized (syn) or further calcined to remove the templates
(cal). The UV-vis spectra of both platinum compounds were
obtained and the intensities of several bands (205-210 nm,
210-220 nm, 220-235 nm, and 300-330 nm) were measured
as functions of drug concentration, showing that these band
intensities could serve to measure drug concentration. Centrifu-
gation of nanoparticle solutions did not suffice to remove the
residue of particles, resulting in a pseudoabsorption in band
regions. Therefore, this pseudoabsorption had to be subtracted
frommeasured band intensities for drug in supernatants in which
the same nanoparticles had been suspended.
Studies of adsorption of cisplatin and transplatin by four
materials (SBAsyn, SBAcal, MCMsyn, and MCMcal), showed
that calcined MCM particles adsorb less cisplatin or transplatin
thanuncalcinedMCMsynparticles, the differencebeing larger for
Figure 6. Band intensities for 205-210 nm (upper panel) and 300-330 nm (lower panel) from platinum drugs remaining in solution after
centrifuging outMCMnanoparticles. Platinum drugs were diluted from the commercial products, without (2) and with 5 mg/mLMCMsyn
(9) or MCMcal (≤). Band intensities were fitted into functions of time. For drug alone (light solid line), the function A - Be-kt was used,
representing the effect of hydrolysis; for drug loaded by either MCMsyn (dark solid line) or MCMcal (dashed line), linear regressions were
adopted. Time zero corresponds to the addition of nanoparticles into the drug solution.
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transplatin. The same is true for SBA particles. The reason for the
decreased adsorption of particles after calcination may be that
calcination changes the nature of the particle surface, such as
by removing residual surfactant, or that there is an enhanced
adsorption of the drugs into the surfactant assemblies or by
replacing them in the as-synthesized materials. Immobilization of
drugs or many organic molecules into surfactant assemblies is not
uncommon.34-36 In fact, additives such asmesitylene and pentane
have been used to swell cylindrical micelles and enlarge their
templated nanopores.37 Consequently, in this case, the surfactant
assembly in the as-synthesized SBAandMCMmay have behaved
as a sponge for physisorption of the drugmolecules, increasing its
adsorption capacity per particle compared to the calcined coun-
terparts. Although HPLC study showed no chemical interaction
between surfactant and drug molecules, it can not rule out the
possible physical interaction (e.g., physisorption). Furthermore,
the platinum species could replace some of the surfactant in the
same way as protons or salt ions substitute them during solvent
extraction in dilute aqueous acidic solution.38 So, thismay also be
responsible for the slightly higher adsorption of the platinum
drugs in the as-synthesized samples compared to their calcined
counterparts. On the basis of particle mass, SBA nanoparticles
adsorb slightly more cisplatin than MCM, and slightly less
transplatin. Possible saturation of the samples by the drug
molecules was checked by measuring band intensities with parti-
cle concentration fixed at 5mg/mLand drug concentration varied
up to 2 mM. If a Langmuir-like isotherm (which includes
saturation)were followed, a plot of drug concentration in solution
after adsorption by nanoparticles vs original drug concentrations
would be curved concave upward, rather than linear. Our results
show clearly that this is not the case.
Adsorption of cisplatin or transplatin in PBS solutions was
measured as a function of time for 5 mg/mL SBA or MCM
nanoparticles. The results indicate that drug is rapidly adsorbed
by all four species of particles. Linear fits were made to plots of
band intensities vs time, for t>1/2 h.After taking drug hydrolysis
into account, we found small negative slopes for SBA particles
(smaller for SBAcal than for SBAsyn), showing that, after the first
1/2 h, there is a slow take-up of drug by these particles, probably
associated with the internal pores or continuous surfactant
assemblies in the SBAsyn case. For MCM particles, on the other
hand, there is no statistical difference between the slopes for
MCMsyn andMCMcal, indicating that either the adsorption into
internal pores or continuous surfactant assembly is less impor-
tant. The external surfaces of the particles as well as likely the
surfactant assemblies in the case of as-synthesized samplesmay be
responsible for the rapid adsorption (for t< 1/2 h). Bymeasuring
Pt band intensities in PBS in which drug-loaded particles were
suspended, we showed there was substantial quick release of both
drugs from all particles, but very little slow release of Pt species,
except for transplatin in SBAcal.
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